SAB Biotherapeutics, Inc. (SABSW) bonds
SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS
$0.01+0.00 (+33.33%)
Close on Oct 20, 2026Market cap $304.80MP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
SAB Biotherapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in SAB Biotherapeutics's 10-K for the period ended Dec 31, 2024
| Issue | Carrying value |
|---|---|
| 8% Unsecured Convertible Note | $0 |
| Insurance Financing Note Payable | $275.85K |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-K.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size |
|---|---|
| Octobernote | $542.00K |